Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

Summary

BCD-085 is an innovative drug, anti-interleukin-17 monoclonal antibody. The aim of the study is to evaluate the efficacy and safety of BCD-085 in patients with primary biliary cholangitis (PBC).

Timeline

Start

2018-04-27

Primary completion

2019-07-01

Completion

2019-07-01

Outcome

Outcome not reported

Stopped: “Sponosor's decision”

Drugs

Indications